

5. Reichardt P. The treatment of uterine sarcomas. *Ann Oncol* 2012;23 (Suppl 10):x151–x157. doi: 10.1093/annonc/mds359.
6. Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. *Expert Rev Anticancer Ther* 2012;12:885–894. doi: 10.1586/era.12.74.
7. Dos Santos LA, Garg K, Diaz JP, Soslow RA, Hensley ML, Alektiar KM, *et al.* Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. *Gynecol Oncol* 2011;121:319–322. doi: 10.1016/j.ygyno.2010.12.363.
8. Zhou J, Zheng H, Wu SG, He ZY, Li FY, Su GQ, *et al.* Influence of different treatment modalities on survival of patients with low-grade endometrial stromal sarcoma: a retrospective cohort study. *Int J Surg* 2015;23:147–151. doi: 10.1016/j.ijsu.2015.09.072.
9. Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, *et al.* Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur J Cancer* 2008;44:808–818. doi: 10.1016/j.ejca.2008.01.019.
10. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics. Available from: <https://seer.cancer.gov/>. [Accessed November 16, 2017]
11. Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, *et al.* Ovarian conservation and overall survival in young women with early-stage cervical cancer. *Obstet Gynecol* 2017;129:139–151. doi: 10.1097/AOG.0000000000001754.
12. Schick U, Bolukbasi Y, Thariat J, Abdahbortnyak R, Kuten A, Igdem S, *et al.* Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. *Int J Radiat Oncol Biol Phys* 2012;82:e757–e763. doi: 10.1016/j.ijrobp.2011.11.005.

How to cite this article: Wang M, Meng SH, Li B, He Y, Wu YM. Survival outcomes of different treatment modalities in patients with low-grade endometrial stromal sarcoma. *Chin Med J* 2019;132:1128–1132. doi: 10.1097/CM9.0000000000000259

Corrigendum

Corrigendum: Analysis of platelet parameters and activation markers in hematologic metastases of lung cancer

In the article titled “Analysis of platelet parameters and activation markers in hematologic metastases of lung cancer” published on pages 735–737, Issue 6, Volume 132 of *Chinese Medical Journal*,^[1] the affiliation of authors is written incorrectly as “Department of Thoracic Surgery, The 96th Hospital of the People’s Liberation Army of China, Jinan, Shandong 250031, China” instead of “Department of Thoracic Surgery, The 960th Hospital of the People’s Liberation Army of China, Jinan, Shandong 250031, China.”

Reference

1. Zhang SS, Zhang M, Yuan L, Zou ZQ. Analysis of platelet parameters and activation markers in hematologic metastases of lung cancer. *Chin Med J* 2019;132:735–737. doi: 10.1097/CM9.0000000000000138.

DOI:10.1097/CM9.0000000000000244